Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Medios AG is a leading provider of specialty pharmaceutical solutions in Germany, specializing in the supply of high-priced medications for rare and chronic diseases. Founded in 2015 and headquartered in Berlin, the company operates primarily through two key segments: Pharmaceutical Supply and Patient-Specific Therapies. The Pharmaceutical Supply segment delivers over 1,000 products targeting critical therapeutic areas including oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia, ensuring reliable access for specialized pharmacies, hospitals, and medical specialists. The Patient-Specific Therapies segment, GMP-certified with advanced cleanrooms, compounds approximately 400,000 individualized preparations annually, such as cytostatic infusions, antibody therapies, virostatic and antibiotic medications, parenteral nutrition solutions, and investigational medicinal products for clinical trials. Medios AG maintains stringent quality standards with temperature-controlled logistics from -80°C to +25°C and supports a Europe-wide network for optimized patient care in individualized medicine. As Germany's market leader in this sector, it plays a pivotal role in enhancing pharmaceutical supply chains for complex disorders.
Operating margin is thin at 2.04%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 10.4%, still solid. Free cash flow declined 35% despite revenue growth, conversion is weakening.
Free cash flow declined 35% versus the prior year, cash generation momentum has weakened.
Profitability & Returns
Revenue (TTM)
€2.12B
▲ +10.4% YoY
Net Income (TTM)
€14M
▲ +22.4% YoY
Op. Margin
1.96%
▲ +0.4pp YoY
ROIC
3.22%
▲ +0.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€52M
▼ -34.7% YoY
Op. Cash Flow (TTM)
€58M
▼ -31.7% YoY
Net Debt
€107M
Cash & Equiv.
€82M
3Y CAGR: +8.9%
3Y CAGR: +11.1%
Continue Research